{ "items": [ "\n\n
\n \n\n \n \n \n \n SMRU\n \n \n \n \n Video\n \n \n\n \n\n\n
\n \n\n \n23 August 2017
\n \n \n \nIn Southeast Asia, some types of the malaria parasite develop resistance to the drug combinations used to cure and prevent the disease. If this drug resistance spread to Africa, it\u2019d be a disaster. Fortunately, partners on the front lines are finding ways to fight back. Watch this video about the amazing work our team of SMRU researchers is doing to combat drug resistance in Thailand.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n21 August 2017
\n \n \n \nChanging home designs and materials to make homes cooler and harder for mosquitoes to enter could reduce malaria transmission in sub-Saharan Africa, according to a new study in The Lancet Planetary Health.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n19 July 2017
\n \n \n \nAn existing malaria rapid diagnostic test (RDT) can be adapted to predict the delayed anaemia that can complicate severe malaria in patients treated with artemisinin-based antimalarial drugs
\n \n\n \n \n\n \n\n \n \n \n \n COMRU\n \n \n\n \n\n\n
\n \n\n \n5 July 2017
\n \n \n \nOn 21 June 2017, the Cambodia Oxford Medical Research Unit (COMRU) and Angkor Hospital for Children (AHC) hosted the kick-off meeting for the multi-country Real-time Tracking of Neglected Bacterial Infectious Diseases Resistance Patterns Asia (TuNDRA) study.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n19 June 2017
\n \n \n \nOn Tues 6 June 2017, researchers vaccinated volunteers and began Mahidol University\u2019s study of the malaria vaccine RTS,S/AS01. This is the first study in Asia of the vaccine, an advanced product that has received regulatory approval in Europe.
\n \n\n \n \n\n \n\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n19 June 2017
\n \n \n \nIt has been maintained for decades that quinine is the safest drug for treatment of malaria in the first trimester of pregnancy. In the largest analysis of data from Thailand and Africa, artemisinins are reported to be at least as safe as quinine. This will simplify treatment protocols worldwide.
\n \n\n \n \n\n \n\n \n \n \n \n LOMWRU\n \n \n\n \n\n\n
\n \n\n \n24 May 2017
\n \n \n \n24 May 2017, Bangkok \u2013 This April and May, the targeted malaria elimination (TME) study in Laos\u2019 final prevalence survey evaluated new tools to detect asymptomatic malaria. These included new rapid diagnostic tests (RDTs) that may be similar in sensitivity to a PCR performed on dried blood spots and reading machines that fire a laser at RDTs and use a thermal camera to detect faint positive results that would be beyond the range of the human eye.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n3 February 2017
\n \n \n \nA lineage of multidrug resistant P. falciparum malaria has widely spread and is now established in parts of Thailand, Laos and Cambodia, causing high treatment failure rates for the main falciparum malaria medicines, artemisinin combination therapies (ACTs)
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n18 January 2017
\n \n \n \nIn the largest study of its kind, a team of researchers led by MORU and WWARN in Bangkok developed a pharmacokinetic model that enabled a revised dose regimen to safely treat all malaria patients including young children with dihydroartemisinin-piperaquine (DP), a widely used antimalarial and a first-line treatment against malaria recommended by the World Health Organization (WHO).
\n \n\n \n \n\n \n\n \n \n \n \n LOMWRU\n \n \n\n \n\n\n
\n \n\n \n14 December 2016
\n \n \n \nProf Paul Newton, Director of LOMWRU and Head of the Medicine Quality Group at the Infectious Diseases Data Observatory IDDO, explains the history of falsified medicines and highlights what needs to be done to avert a problem that threatens us all.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n1 December 2016
\n \n \n \nIn a first, scientists used computer simulations to identify the vaccines most likely to be effective against respiratory syncytial virus (RSV), the most common cause of infant severe pneumonia worldwide.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n24 November 2016
\n \n \n \nThis week marks the opening of a series of performances of Fishy Clouds, a MORU collaboration with innovative Bangkok-based B-floor Theatre group. Produced following a 6-month WT-funded research residency at MORU, Fishy Clouds is a 40-45 minute puppet theatre performance that focuses on antimicrobial resistance and the ethics of research with children. It is part of MORU's Public Engagement activities to make science more accessible to a wider public including children and young people.
\n \n\n \n \n\n \n\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n18 October 2016
\n \n \n \nTraining local Karen and Burman women as skilled birth attendants in refugee settings resulted in no adverse perinatal outcomes and many positive outcomes such as a drop in stillbirths and infant deaths and more babies being born in clinics rather than at home, says a new study published in the scientific journal PLOS ONE.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n14 September 2016
\n \n \n \nMultidrug-resistant bacterial infections cause more than 19,000 excess deaths a year in Thailand alone, according to a study published today in eLife Sciences Publications. In a first for Thailand, the study systematically examined microbiology laboratory and hospital databases from nine public hospitals in Northeast Thailand and compared them to Thailand\u2019s national death registry to estimate that 19,122 deaths in Thailand in 2010 were excess deaths caused by multidrug-resistant bacterial infections.
\n \n\n \n \n\n \n\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n28 June 2016
\n \n \n \nThe rapid decline in effectiveness of a widely used anti-malaria drug treatment on the Thailand-Myanmar border is linked to the increasing prevalence of specific mutations in the malaria parasite itself, according to a paper published in The Clinical infectious Disease Journal.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n18 May 2016
\n \n \n \nNew and unexpected health threats have emerged in Asia that could weigh on the world's fastest growing and most dynamic region. Diseases associated with obesity and smoking are rising, and will cause tens of millions of deaths from heart and lung disease and cancer in coming decades. But alongside these lifestyle-associated conditions, the old foe of infectious disease is reemerging and threatens to cause an even greater health and economic disaster.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n4 May 2016
\n \n \n \nNo one knows exactly why resistance to malaria drugs always emerges first in this remote western province of Cambodia, nestled in the Cardamom Mountains. \u201cThe reasons are as much social as biological,\u201d says malariologist Tom Peto, who is here in this dusty, unremarkable-looking town battling the latest threat to global malaria control: multiple drug\u2013resistant (MDR) malaria.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n21 March 2016
\n \n \n \nThe Tracking Resistance to Artemisinin Collaboration II (TRACII) study has begun recruitment, with about 180 subjects enrolled to date in 12 sites in seven countries in Asia and Africa, researchers announced at the second TRACII investigators\u2019 meeting held 7 March in Bangkok.
\n \n\n \n \n\n \n\n \n \n \n \n MORU Bangkok\n \n \n\n \n\n\n
\n \n\n \n14 March 2016
\n \n \n \nDr Joel Tarning from MORU discusses his New England Journal of Medicine editorial on treating malaria in pregnancy, outlining new evidence on the effectiveness of artemisinin-combination therapies in pregnant women with malaria.
\n \n\n \n \n\n \n\n \n \n \n \n SMRU\n \n \n\n \n\n\n
\n \n\n \n11 February 2016
\n \n \n \nArtemisinins, the most effective antimalarials available, should be endorsed in the first trimester of pregnancy to ensure optimal treatment of falciparum malaria in pregnant women, reports a paper published today in The Lancet Infectious Diseases.
\n \n\n \n \n